Clinical Trial

BCMA-CD19 cCAR T for the Treatment of Refractory Lupus

Name: BCMA-CD19 cCAR T for the Treatment of Refractory Lupus — clinical trial record (NCT07328581)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19-IL-15/IL15sushi cCAR T cells in patients with relapsed and/or refractory SLE, with or without Lupus Nephritis.

Trial Details

NCT Number	NCT07328581
Lead Sponsor	iCell Gene Therapeutics
Conditions	Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Enrollment	20 participants
Start Date	2026-01
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-01-09